Comprehensive Analysis of Mouse Cancer/Testis Antigen Functions in Cancer Cells and Roles of TEKT5 in Cancer Cells and Testicular Germ Cells by Nana Aoki & Yasuhisa Matsui
Comprehensive Analysis of Mouse Cancer/Testis
Antigen Functions in Cancer Cells and Roles of
TEKT5 in Cancer Cells and Testicular Germ
Cells
著者 Nana Aoki, Yasuhisa Matsui
journal or
publication title









Comprehensive analysis of mouse CTA functions in cancer cells and roles of TEKT5 in 1 
cancer cells and testicular germ cells 2 
 3 
Nana Aokia,b, and Yasuhisa Matsuia,b,c,d# 4 
 5 
aCell Resource Center for Biomedical Research, Institute of Development, Aging and 6 
Cancer, Tohoku University, Sendai, Miyagi, Japan 7 
bGraduate School of Life Sciences, Tohoku University, Sendai, Miyagi, Japan 8 
cGraduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan 9 
dThe Japan Agency for Medical Research and Development-Core Research for 10 
Evolutional Science and Technology (AMED-CREST), Tokyo, Japan,  11 
 12 
Running Head: TEKT5 functions in cancer and germ cells 13 
 14 
#Address correspondence to Yasuhisa Matsui, yasuhisa.matsui.d3@tohoku.ac.jp 15 
 16 
Key words: germ cell, cancer cell, CTA, Tekt5 17 





The cancer/testis antigen (CTA) genes were identified as human genes preferentially 21 
expressed in cancer cells and testis, but the contribution of CTAs to cancer and male 22 
germ cell development is unclear. In this study, we comprehensively examined mouse 23 
CTA functions, and found that the majority of CTAs are involved in growth and/or 24 
survival of cancer cells. We focused on one mouse CTA gene, Tekt5, for its detailed 25 
functional analysis. Tekt5 knock-down (KD) in ovarian cancer cells caused G1 arrest and 26 
apoptosis, and p27kip1 was concomitantly up-regulated. Tekt5 KD also resulted in 27 
decreased levels of acetylated (ac) -α-tubulin and subsequent fragmentation of 28 
β-III-tubulin; up-regulation of HDAC6 that deacetylates α-tubulin; and nuclear 29 
accumulation of SMAD3 that induces p27kip1 expression. Because depolymerization of 30 
tubulin is known to cause translocation of SMAD3 to the nucleus, these results together 31 
suggested that TEKT5 negatively regulates Hdac6 expression and consequently 32 
maintains cell cycle via stabilization of tubulin. We also found that the number of 33 
spermatids was significantly decreased and ac-α-tubulin levels were decreased in vivo by 34 
KD of Tekt5 in testis. Because ac-α-tubulin is required for sperm morphogenesis, these 35 
results suggest that TEKT5 is necessary for spermiogenesis via maintenance of 36 
ac-α-tubulin levels.  37 
 38 
INTRODUCTION 39 
Cancer/testis antigen (CTA) genes are a group of genes that are preferentially 40 
expressed in cancer and testis. De Smet et al. identified MAGE-1 as a gene encoding an 41 
 
 3 
antigen present on melanoma cells; the gene then was designated as a CTA gene based on 42 
its specific expression in cancer cells and testis (1). Subsequently, examination of tumor 43 
specimens and patient sera have led to reports of approximately 270 human CTA genes to 44 
date (CTDatabase, http://www.cta.lncc.br/index.php). The roles of some CTA genes in 45 
cancer cells and germ cells have been defined. For instance, genes belonging to the 46 
MAGE-A and SSX family enhance the Epithelial-Mesenchymal Transition (EMT) of 47 
cancer cells and the development of cancer stem cells, and accelerate tumor development 48 
and metastasis (2). In addition, CTAs could be good bio-markers for cancer, and some 49 
CTAs such as MAGE-A4 have been applied for cancer immune-therapy (3). In germ 50 
cells, CTAs such as SYCP1 and SYCE2 are involved in formation of the synaptonemal 51 
complex in meiotic prophase (4, 5). Nevertheless, CTAs whose functions are critical in 52 
both cancer cells and germ cells are unknown. It is likely that some CTAs share related 53 
molecular mechanisms, playing distinct or similar functions in cancer cells and germ 54 
cells.  55 
To find CTAs that function both in cancer cells and germ cells, we first selected 56 
mouse CTA genes that are highly expressed in cancer cells, because use of the mouse 57 
model is expected to facilitate functional evaluation of the CTAs in testicular germ cells 58 
in vivo. We then carried out functional screening of mouse CTA genes by knock-down 59 
(KD) using RNA interference (RNAi) in mouse cancer cell lines in which the 60 
corresponding CTA genes are highly expressed. As a result, we identified the mouse 61 
Tektin 5 (Tekt5) gene, a homologue of a locus that originally was reported as a CTA gene 62 
highly expressed in human colon cancer and whose expression subsequently was detected 63 
in various cancer cells (6). TEKT5 is a member of the Tektin protein family; some 64 
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members of this family have been suggested to be components of cilia and flagella 65 
composed of microtubules (7). Among members of the Tektin family, TEKT1, 2, 3, and 4 66 
have been shown to localize within the entire sperm tail, while TEKT5 has been found to 67 
localize only in the mitochondrial sheath in the mid-piece of the rat sperm tail (8). 68 
However, TEKT5’s function(s) in cancer cells as well as in testicular germ cells are 69 
unknown. In the present study, we showed that TEKT5 controls tubulin stability to 70 
enhance the growth and survival of cancer cells and to promote sperm morphogenesis. 71 
 72 
RESULTS 73 
Identification of mouse CTA genes. CTA genes originally were identified as human 74 
genes, but systematic identification of mouse CTA genes has not been reported (to our 75 
knowledge). To facilitate examining the functions of CTAs in germ cells in vivo, we 76 
sought to identify mouse CTA genes, and explored mouse homologues of human CTA 77 
genes by using a web tool, Homologene Matcher 78 
(http://refdic.rcai.riken.jp/tools/matchom.cgi). Using this program, we identified 139 79 
mouse homologue genes (Table S1) from 277 human CTA genes. The smaller number of 80 
mouse genes is due, in part, to the existence of human-specific gene families such as 81 
GAGE (9), XAGE (10), PAGE (11), and BAGE (12) among the human CTA genes. 82 
   Among the 139 mouse homologue genes, we excluded 13 genes (Ctage5, Cntn2, 83 
Spag9, Kif20b, 2610507B11Rik, Otoa, Lypd6b, Igsf11, Tmem108, RqCd1, 84 
2410076I21Rik, Hemgn, and Stk38) that appear not to be expressed in testis, as judged by 85 
a web tool, BioGPS (http://biogps.org/#goto). Suitable PCR primers were not designed 86 
for another 14 genes that also were excluded. Using RT-qPCR, we examined the 87 
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expression of the remaining 112 genes in mouse cancer cell lines and corresponding 88 
normal tissues as well as in testis (Fig. 1, 2；Table S2). Most of the tested genes were 89 
highly expressed in testis compared with the tested cancer cells and normal tissues (Table 90 
S2). We selected 87 genes showing higher expression in at least one of the tested cancer 91 
cell lines compared with the corresponding normal tissues (Fig. 1; Table S3).  92 
Screening of mouse CTAs involved in growth or survival of cancer cells. To 93 
identify functionally important CTAs in cancer cells, we estimated the effects of KD of 94 
mouse CTA genes on growth or survival of cancer cells. Among 87 genes highly 95 
expressed in mouse cancer cell lines, we excluded 3 genes (Sycp1, Spo11, Spef2) for 96 
which siRNAs were not commercially available. We carried out KD of the remaining 84 97 
genes by introducing two different siRNAs corresponding to each CTA gene into the 98 
cancer cell lines and estimating changes in cell number. Those lines included melanoma 99 
(B16 (13), B16C2W (14)), lung tumor (3LL (15), KLN205 (16)), breast tumor (Ehrlich 100 
(17), MM46 (18), FM3A (19)), liver tumor (Hepa1-6 (20), MH134-TC (21)), bladder 101 
tumor (MBT-2 (22)), ovarian tumor (OV3121 (23), OV2944-HM-1 (24)), and colon 102 
tumor (colon-26 (25)) cells. The combinations of genes and tested cell lines are shown in 103 
Table S4. 104 
We first introduced the siRNAs into a first cell line, one in which the expression of 105 
the corresponding CTA gene was highest among the tested cell lines, and selected 47 106 
genes whose KD reproducibly resulted in changes in cell number that exceeded 10% of 107 
control cell number (Fig. 3; Table S5). Among those 47 genes, we selected 21 genes 108 
whose expression was higher in more than one cancer cell line compared with that in the 109 
corresponding normal tissue (Fig. 1; Table S3). We then tested those 21 genes for KD in 110 
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a second cell line, one that showed the next highest level of expression of the respective 111 
gene, and obtained 10 genes whose KD resulted in changes in cell number that exceeded 112 
10% of control cell number (Fig. 4; Table S6). Among those 10 genes, KD of 3 genes 113 
(Tekt5, Akap3, and Magea5) caused changes in cell number of more than 30% in both the 114 
first and the second cell lines (Fig. 3; Fig. 4). In subsequent work, we focused on Tekt5 115 
for detailed analysis, because the function(s) of Tekt5 in both cancer cells and germ cells 116 
are unknown.  117 
Cell-cycle enhancement of cancer cells by TEKT5 via regulation of the 118 
tubulin-SMAD axis. We first confirmed that cell number of OV3121 and MH134-TC 119 
was significantly decreased after 48 and 72 hours of Tekt5-KD by either of two different 120 
siRNAs (Fig. 5A, B). This decrease in cell number was accompanied by decreases in the 121 
accumulation of both the Tekt5 mRNA and the TEKT5 protein (Fig. 5C, D). We then 122 
tested whether cell-cycle progression and/or cell survival were affected by Tekt5-KD. We 123 
found increased numbers of apoptotic cells, as well as a prolonged G1 phase and 124 
shortened G2 phase within the cell cycle (Fig. 5E, F). Because p27kip1, a cyclin-dependent 125 
kinase inhibitor, is known to repress the G1-S transition (26), we examined expression of 126 
this protein, and demonstrated that the p27kip1 protein accumulated to higher levels in 127 
Tekt5-KD cells (Fig. 5G).  128 
Previous studies have shown that the expression of p27kip1 is enhanced by SMADs, a 129 
family of TFG β-signaling molecule that includes SMAD3 (27, 28). In addition, some 130 
members of the Tektin family of proteins have been suggested to be components of cilia 131 
and flagella consisting of microtubules (7, 29); dissociation of SMADs from 132 
microtubules after microtubule depolymerization permits the activation of SMADs, 133 
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resulting in the transmission of a signal to the nucleus (30). We therefore tested whether 134 
localization of SMAD3 was affected by Tekt5-KD in OV3121; as expected, Tekt5-KD 135 
resulted in increased levels of nuclear SMAD3 (Fig. 5H). We also examined effects on 136 
tubulin, and found that the fibrous appearance of β-III-tubulin was disrupted upon of 137 
Tekt5-KD (Fig. 6A). Meanwhile, we observed that TEKT5 did not colocalize with 138 
β-III-tubulin (Fig. 6B). Together, these results suggest that, unlike other members of 139 
Tektin family, TEKT5 is not associated with tubulin, and may affect tubulin stabilization 140 
only indirectly. 141 
Because tubulin is stabilized by acetylation (31), we next examined levels of 142 
acetylated α-tubulin. The results showed that ratios of acetylated α-tubulin to total 143 
α-tubulin in OV3121 were decreased by Tekt5-KD (Fig. 6C). We also found that the 144 
expression of HDAC6, a protein known to de-acetylate α-tubulin (32), was up-regulated 145 
by Tekt5-KD (Fig. 6D). In addition, tubastatin A (TBSA), a specific inhibitor of HDAC6 146 
(33), rescued Tekt5-KD-induced de-stabilization of β-III-tubulin in OV3121 (Fig. 7A). In 147 
addition, TBSA improved the cell viability of Tekt5-KD cells but not that of control cells 148 
(Fig. 7B). These results implied that TEKT5 is involved in the stabilization of tubulin via 149 
negative regulation of HDAC6 expression, which consequently results in cell cycle 150 
progression via attenuation of SMAD3 translocation and of p27kip1 induction (Fig. 7C). 151 
Roles of TEKT5 in spermiogenesis. Reanalysis of transcriptome data from a public 152 
data base (GenBank accession number GSE4193) (34) revealed that the expression of 153 
Tekt5 is gradually up-regulated during spermatogenesis (Fig. 8A). Using immunostaining, 154 
we confirmed that TEKT5 protein expression accumulates in testis from the late 155 
pachytene stage on (Fig. 8B, C). 156 
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We then examined the in vivo functions of Tekt5 by performing KD in testis. We 157 
introduced siRNAs corresponding to Tekt5 and a control into the seminiferous tubules of 158 
the left and right testes, respectively, in 8-day old mice (35), and evaluated the testes 159 
histologically at 14 and 21 days after injection of the siRNAs. Abnormal spermatogenesis 160 
was observed in some seminiferous tubules (Fig. 9A) in Tekt5 siRNA-injected testes. We 161 
confirmed decreased accumulation of both Tekt5 mRNA (Fig. 9B) and TEKT5 protein 162 
(Fig. 9C) in Tekt5 siRNA-injected testis (i.e., Tekt5-KD testis). Ratios of tubules with 163 
spermatids labeled by peanut agglutinin (PNA) were decreased in Tekt5-KD testis 164 
compared with those in control testis, while SYCP3-expressing spermatocytes were not 165 
affected (Fig. 9D). These results indicated that TEKT5 is involved in spermatid 166 
differentiation. We also observed decreased levels of acetylated α-tubulin in Tekt5-KD 167 
testis (Fig. 9E). Furthermore, the transcriptome analysis (in normal development) showed 168 
that Hdac6 transcript levels fell during spermatogenesis, concomitant with increased 169 
Tekt5 transcript accumulation (Fig. 8A; Fig. 9F). Together, these results implied that 170 
TEKT5 contributes to spermiogenesis by maintaining the levels of acetylated α-tubulin. 171 
 172 
DISCUSSION 173 
Among 139 mouse homologues of human CTA genes, we identified 87 genes as 174 
mouse CTA genes (Fig. 1; Table S3), loci that showed higher expression in at least one of 175 
the tested cancer cell lines when compared with expression in corresponding normal 176 
tissues. Differences in the transcript levels (between the cancer cells and normal tissues) 177 
were not obvious for the rest of the genes (Fig. 2). It is likely that the correct counterparts 178 
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of some human CTA genes were not selected by the web tool, or that the tested cancer 179 
cells express the tested genes only at low levels.  180 
Our RNAi screening showed that KD of 47 out of 84 genes caused more than 10% 181 
changes of cell number in cancer cell lines (Fig. 3, 4; Table S5), suggesting that the 182 
majority of CTAs are involved in cancer cell development. It is worth noting that some of 183 
those CTA genes whose KD affected cancer cell number in culture are known to be 184 
mutated in human cancers. For instance, MORC1 typically is mutated in metastatic breast 185 
cancer, though the frequency of mutation of this gene is low in primary breast cancer (36). 186 
In a second example, a truncating mutation in the TEX15 open reading frame was 187 
identified as a possible risk factor for breast cancer (37). In a third example, frame-shift 188 
mutations of TTK and TAF7L are commonly found in gastric and colorectal cancers (38, 189 
39). Involvement of these mutations in cancer development is currently obscure, but our 190 
results suggest that various CTAs play a role in cancer cells, including instances other 191 
than those previously reported for members of the MAGE-A and SSX family. 192 
KD of mouse CTA genes did not necessarily result in decrease in cell number; indeed, 193 
the KD of some CTA genes caused increases in cell number (Fig. 3; Fig. 4), indicating 194 
that these genes may normally encode negative regulators of the growth and/or survival 195 
of cancer cells. This observation implies that, in some cases, these CTAs are involved in 196 
growth suppression of cancer cells, a process that might include metastasis-associated 197 
growth suppression (40). KD of some CTA genes did not yield consistent effects on cell 198 
number in different cancer cell lines (Fig. 3; Fig. 4), suggesting that CTAs may serve 199 
functions or be required differentially in various cancer cell lines. 200 
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We found that Tekt5 KD caused accumulation of OV3121, an ovarian cancer cell line, 201 
in the G1 phase of cell-cycle, with a concomitant increase in the fraction of apoptotic 202 
cells (Fig. 5E, F). These observations implied that TEKT5 positively regulates cell cycle 203 
progression. Consistent with this inference, p27kip1, a cyclin-dependent kinase inhibitor 204 
known to repress the G1-S transition, accumulated to higher levels in Tekt5 KD cells (Fig. 205 
5G). Our results suggested that destabilization of tubulin by Tekt5 KD causes nuclear 206 
accumulation of SMAD3 (Fig. 5H; Fig. 6A), which is known to up-regulate p27kip1 (27, 207 
28). This inference also is consistent with a previous report showing that SMADs are 208 
activated by dissociating from microtubules after microtubule de-polymerization (30). 209 
Meanwhile, previous studies indicated that destabilization of tubulin resulted in 210 
translocation of some transcription factors such as myc-interacting zinc finger protein 211 
(MIZ-1) (41) and NF-κB (42) from cytoplasm to nucleus, and we cannot exclude a 212 
possibility that additional unknown factors other than SMAD3 might translocate into 213 
nucleus by Tekt5 KD via tubulin destabilization to repress cell-cycle.  214 
Additionally, a previous study also showed that nuclear accumulation of α, β-tubulins 215 
induced by their depolymerization by nocodazole treatment at 4°C or by inhibiting their 216 
nuclear export resulted in G0/G1 arrest and apoptosis of cells, and nuclear tubulins was 217 
associated with histone H3, which may affect chromatin organization (43). Because we 218 
found that a part of β-III-tubulin was ectopically localized in nucleus by Tekt5 KD (Fig. 219 
6A), Tekt5 KD likely induces cell-cycle arrest and apoptosis via nuclear tubulin in 220 
addition to nuclear SMAD3 (Fig. 7C). We also observed prominent DAPI-stained dots in 221 
nucleus by Tekt5 KD (Fig. 6A inlets), which may reflect not only apoptosis, but also 222 
changes of chromatin organization induced by Tekt5 KD. 223 
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Contrary to the known localization of other Tektin family proteins in cilia and flagella 224 
(29), TEKT5 did not co-localize with microtubules (Fig. 6B), although TEKT5 is 225 
involved in Hdac6 gene expression (Fig. 6D, E). The mechanisms of possible 226 
transcriptional regulation of Hdac6 by TEKT5 are currently unclear, but cytoplasmic 227 
localization of TEKT5 implies its interaction with signaling molecules to transmit signals 228 
to the nucleus and subsequent down-regulation of Hdac6 expression.  229 
Although TBSA effectively rescued the disruption of tubulin by Tekt5 KD in OV3121 230 
cells (Fig. 7A), TBSA’s effect in counteracting the attenuation of cell viability by Tekt5 231 
KD was marginal (Fig. 7B). These observations suggested that additional modifications 232 
of tubulins are involved in their stabilization and subsequent enhancement of cell 233 
viability by TEKT5 (Fig.7C). For instance, it was previously reported that 234 
hyper-elongation of glutamyl side chains stabilized cytoplasmic microtubules in 235 
Tetrahymena (44). Consistently, a modest amount of β-III-tubulin was observed in 236 
nucleus even in the presence of TBSA (Fig.7A), which may explain why the effect of 237 
TBSA on the attenuation of cell viability by Tekt5 KD was marginal; further 238 
characterization of all these effects will be an important subject for future studies. 239 
We observed spermatogenic failures, including abnormal spermiogenesis, upon in 240 
vivo KD of Tekt5 (Fig. 9). Notably, we observed significant down-regulation of TEKT5 241 
and the abnormal spermatogenesis at 14 days after siRNA injection into testicular tubules 242 
(Fig. 9A), but the influences of Tekt5 KD was not obvious at 21 days after injection (Fig. 243 
9A). This distinction was presumed to reflect the transient nature of effects of the in vivo 244 
KD method, as reported previously (35). We injected siRNA into testicular tubules at 245 
postnatal day (P) 8, in accord with the previous report, and observed the testes 246 
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histologically at P22, when the first round of spermatogenesis is still in progress and 247 
mature sperm have not yet emerged. Although TEKT5 has been shown to localize to the 248 
mid-piece of sperm, we did not observe sperm abnormalities at P29, 21 days after 249 
injection of siRNA, presumably due to diminished influence of the siRNA and recovery 250 
of spermiogenesis in unaffected spermatogenic cells. Additionally, it is also likely that 251 
TEKT5 may not have functions in mature sperm. In this study, we showed a function of 252 
TEKT5 in spermiogenesis in the first-wave spermatogenesis in pubertal testis due to the 253 
limitation of the KD method, and further studies are needed to clarify its functions in 254 
adult testes. 255 
When a round spermatid elongates to form a sperm in the final stage of 256 
spermiogenesis, tubulin is rearranged to form the manchette, a structure that likely is 257 
involved in nuclear elongation and the spiral arrangement of mitochondria in the 258 
mid-piece of the sperm (45, 46). In Tekt5 KD testis, the level of acetylated α-tubulin was 259 
decreased in not only spermatids, but also in PNA-negative late spermatocytes (Fig. 9E), 260 
implying that TEKT5 normally functions in manchette formation via tubulin stabilization. 261 
During spermatogenesis, the accumulation of Tekt5 transcript is increased (Fig. 8A), 262 
while that of Hdac6 transcript is decreased (Fig. 9F). Together, these observations 263 
suggest that TEKT5 negatively controls Hdac6 transcription in testis, as observed in 264 
cancer cells (Fig. 6D); however, immunostaining did not detect significant HDAC6 265 
accumulation even in control testis (data not shown). It is likely that additional HDACs 266 
and/or histone acetylating enzymes are involved in controlling the acetylation of tubulin 267 
in spermatogenic cells.  268 
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Our results show that a single CTA gene, Tekt5, plays crucial roles in both cancer 269 
cells and testicular germ cells. Furthermore, our data imply that one or more other CTAs 270 
also function in both of those cell types. Analysis of the functions of these other CTAs 271 
may uncover distinct cellular regulation in cancer cells and testicular germ cells 272 
controlled by a related molecular mechanism. 273 
 274 
MATERIALS AND METHODS 275 
Cell culture. Cancer cell lines obtained from Cell Resource Center for Biomedical 276 
Research (Tohoku University, Japan) included B16 (mouse melanoma), B16C2W (mouse 277 
melanoma), 3LL (mouse lung cancer), KLN205 (mouse lung cancer), Ehrlich (mouse 278 
breast cancer), MM46 (mouse breast cancer), FM3A (mouse breast cancer), MH134-TC 279 
(mouse liver cancer), and colon-26 (mouse colon cancer). Cancer cell lines obtained from 280 
Riken Cell Bank (Japan) included OV2944-HM-1 (HM-1; mouse ovarian cancer), 281 
Hepa1-6 (mouse liver cancer), and MBT-2 (mouse bladder cancer). OV3121, a mouse 282 
ovarian granulosa carcinoma cell line, was obtained from JCRB Cell Bank (Japan). B16, 283 
B16C2W, 3LL, Ehrlich, MM46, MH134-TC, MBT-2, OV3121, and colon-26 cells were 284 
cultured in RPMI-1640 (Sigma-Aldrich) medium containing 10% fetal bovine serum 285 
(FBS). KLN205 cells were cultured in MEM (Sigma-Aldrich) medium containing 10% 286 
FBS and non-essential amino acids. HM-1 and Hepa1-6 cells were cultured in a-MEM 287 
and DMEM containing 10% FBS, respectively. All cell lines were cultured at 37°C in a 288 
5% CO2 environment. 289 
Mouse strains. C57BL/6J mice were purchased from Japan SLC. The mice were 290 
maintained and bred in the Animal Unit of the Institute of Development, Aging and 291 
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Cancer (Tohoku University), an environmentally controlled and specific-pathogen-free 292 
facility, according to the guidelines for experimental animals defined by the facility. 293 
Animal protocols were reviewed and approved by the Tohoku University Animal Studies 294 
Committee. 295 
Antibodies. The following primary antibodies were used for western blotting: rabbit 296 
anti-glyceraldehyde-3-phosphate dehydrogenese (GAPDH) at 1:2000 (CST, #2118), 297 
rabbit anti-TEKT5 at 1:1000 (Thermo, PA5-21157), mouse anti-p27kip at 1:500 298 
(SantaCruz, sc-1641), mouse anti-acetylated-alpha-tubulin at 1:1000 (SantaCruz, 299 
sc-23950), mouse anti-alpha-tubulin at 1:1000 (Wako, 017-25031), and rabbit 300 
anti-HDAC6 at 1:1000 (CST, #7612). The following primary antibodies and reagent were 301 
used for immunofluorescence assays: rabbit anti-beta-III-tubulin at 1:200 (Sigma-Aldrich, 302 
T2200), rabbit anti-TEKT5 at 1:200 (Thermo, PA5-21157), rabbit anti-SMAD3 at 1:400 303 
(Abcam, ab40854), mouse anti-SYCP3 at 1:400 (Abcam, ab97672), mouse 304 
anti-alpha-tubulin at 1:400 (Wako, 017-25031), and Alexa Fluor 488-conjugated lectin 305 
PNA at 1:500 (Molecular Probes, L-21409). 306 
   In vitro RNAi. The identities of the siRNAs used in screening are listed in Table S3. 307 
siRNAs for Tekt5-KD in cancer cells were prepared as follows: Tekt5 siRNA#1 308 
(QIAGEN, SI00831887), Tekt5 siRNA#2 (QIAGEN, SI00831894), AllStars Negative 309 
Control siRNA (QIAGEN, SI03650318). siRNAs were transfected into cells using 310 
Lipofectamine RNAiMAX (Invitrogen) and the reverse method according to the 311 
manufacturer’s instructions. Briefly, transfection was performed in a 24-well format as 312 
follows. Lipofectamine RNAiMAX (2 l) and siRNA (20 pmol) were diluted with 100 l 313 
Opti-MEM and incubated for 20 min. The mixtures of cells and Lipofectamine were 314 
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seeded onto a 24-well plate. The cells were incubated for 24 h and the medium then was 315 
replaced.  316 
Real-time PCR. Total RNA was extracted from paraffin-embedded tissues or cells 317 
using the RNeasy Plus Mini Kit (QIAGEN) or RNeasy FFPE kit (QIAGEN) according to 318 
the manufacturer’s instructions. RNAs were reverse-transcribed using SuperScript III and 319 
random primers. Real-time PCR was performed using the Power SYBR Green PCR 320 
Master Mix (Applied Biosystems). Thermal conditions were as follows: 2 min at 50 °C, 321 
10 min at 95 °C, and 45 cycles of 15 sec at 95 °C and 60 sec at 60 °C. Sequences of the 322 
primers used for the PCR are shown in Table S7. The housekeeping gene Arbp (which 323 
encodes a mouse ribosomal protein) was used as an internal control. The relative 324 
expression was analyzed using the comparative Ct method. If a Ct value was not obtained 325 
in 45 cycles of amplification, the expression level was considered as 0. 326 
High-throughput RT-qPCR. cDNA was mixed with PreAmp Master Mix 327 
(Fluidigm) and STA Multiplex Primer Pool. Subsequently, the cDNA was amplified by 328 
adding primers and subjecting the mixture to 14 cycles of 95 °C for 15 s (denaturating) 329 
and 60 °C for 4 min (annealing and amplifying). Nested PCR was carried out on the 330 
primary PCR products to ensure specific detection of the transcripts. A list of the primers 331 
used for gene expression analyses is provided in Table S1. The pre-amplified products 332 
were diluted 5-fold before further analysis, then mixed with 2x SsoFast EvaGreen Super 333 
mix with Low ROX (Bio-Rad) and 20x DNA Binding Dye Sample Loading Reagent 334 
(Fluidigm). The mixtures containing the samples, primer pair mix, and 2x Assay Loading 335 
Reagent (Fluidigm) were used as probes against 48.48 Dynamic Arrays on a BioMark 336 
System (Fluidigm). Ct values were calculated by using the system software (BioMark 337 
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Real-time PCR Analysis; Fluidigm). The expression value of each gene was calculated by 338 
the comparative Ct method using the housekeeping gene Hrpt (which encodes 339 
hypoxanthine guanine phosphoribosyl transferase 1) as an internal control. 340 
   Western blotting. For extraction, cells were resuspended in lysis buffer (50 mM 341 
Tris-HCl, 1% SDS, 1x cOmplete™ (Roche), and 1x PhosStop™ (Roche)) and sonicated 342 
using a BIORUPTOR (SONIC BIO) for 5 cycles of 30 s on-and-off at the “high” setting. 343 
The resulting protein extracts were subjected to electrophoresis on NuPAGE 10% 344 
Bis-Tris Gels (Invitrogen) and then transferred to polyvinylidene difluoride membranes 345 
(Millipore Immobilon-P). The membranes were washed in Tris-buffered saline 346 
containing 0.05% Tween 20 (TBST) and blocked for 1 h with TBST containing 5% skim 347 
milk or 5% bovine serum albumin (BSA). The membranes then were incubated overnight 348 
at 4 ºC with the indicated primary antibodies diluted in TBST containing 1% skim milk 349 
or 5% BSA. After washing, the membranes were incubated for 1 h at room temperature 350 
(RT) with horseradish peroxidase-labeled secondary antibodies. Immunoblotting was 351 
visualized using the Clarity Western ECL substrate kit (Bio-Rad) and the LAS-3000 352 
system (Fujifilm). After the images were captured, the membranes were washed for 20 353 
min at 50 ºC with Stripping Buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM 354 
Tris-HCl, pH 6.8), washed with TBST, blocked as above, and incubated for 1 h at RT 355 
with the next antibody (as indicated) . The intensity of the target bands was assessed 356 
using Multi Gauge software (Fujifilm).  357 
MTS assay. Cell proliferation rates were assessed by the MTS 358 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 359 
2H-tetrazolium) assay. Briefly, following culturing in 96 well-plates, cells were incubated 360 
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for 3 h at 37 °C with 20 μl/well of MTS (Promega, G3580). The level of cellular 361 
proliferation was determined by MTS conversion to formazan using a SpectraMax Me2 362 
(Molecular Devices) at 490 nm. 363 
Active caspase analysis. Analysis for active caspase was performed using the 364 
Caspase-3, Active Form, mAb Apoptosis Kit: FITC (BD Pharmingen) according to the 365 
manufacturer’s instructions. The cells were dissociated to yield a single-cell suspension, 366 
washed, and fixed with BD cytofix/cytoperm. The cells then were washed and incubated 367 
for 30 min at RT with the kit-supplied antibody. Fluorescence-activated cell-sorting 368 
analysis of these stained cells was performed on a Cytomics™ FC500 cell analyzer 369 
(Beckman Coulter). 370 
Cell cycle analysis. Cell cycle analysis was performed using the APC BrdU Flow Kit 371 
(BD Pharmingen) according to the manufacturer’s instructions. The cells were 372 
dissociated to yield a single-cell suspension, washed, and fixed with BD cytofix/cytoperm. 373 
The cells then were incubated with DNase and RNase A in BD perm/wash for 1 h at 374 
37 °C, washed, and incubated with 7-AAD (7-amino-actinomycin D) for 1 h at 37 °C. 375 
Fluorescence-activated cell-sorting analysis of these cells was performed on a 376 
Cytomics™ FC500 cell analyzer. 377 
Immunofluorescence. Cells were grown on poly-L-lysine-coated, glass-bottom 378 
dishes. After washing, the cells were fixed in 4% paraformaldehyde buffer solution or 379 
iced methanol and permeabilized for 15 min at RT with phosphate-buffered saline (PBS) 380 
containing 0.1% Triton X-100. The cells then were washed with PBS, blocked for 1 h at 381 
RT with 10% FBS, washed again, and incubated for 1 h at RT with a secondary antibody 382 
diluted in 10% FBS. The resulting samples were mounted with Vectashield Mounting 383 
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Medium (Vector Laboratories), and all images were captured with Leica TSC SP8 (Leica 384 
Microsystems). The intensity of the fluorescence was assessed using Leica Imaging 385 
software (Leica Microsystems).  386 
In vivo knock-down (KD). The Mouse Accell SMART Pools of siRNAs used for the 387 
in vivo KD experiments were prepared using either Tekt5 siRNAs (Dharmacon, 388 
E-051627-00-0020) or non-targeting siRNAs (Dharmacon, D-001910-10-05). siRNA 389 
solutions were formulated in Dulbecco’s PBS containing 100 μM Accell siRNAs, 1x 390 
siRNA buffer (Dharmacon), and 0.01% trypan blue solution (Sigma-Aldrich) (as a tracer). 391 
Solutions of Tekt5 siRNA or control siRNA were microinjected into the seminiferous 392 
tubules of the left and right testes, respectively, in live mouse pups, using the method 393 
described by Dai et al. (35). Briefly, each mouse (8 days old) was anesthetized with ice. 394 
Testes were pulled out from the abdominal cavity and (working under a binocular 395 
microscope) approximately 3 μl of siRNA solution was injected into the rete testis using a 396 
glass capillary. The testes then were returned to the abdominal cavity, and the abdominal 397 
wall and skin were closed with sutures. The mouse was placed on a hot plate at 37 °C 398 
until awake. 399 
Hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) 400 
staining. Testes were fixed in 4% paraformaldehyde buffer solution and embedded in 401 
paraffin. Sections (5-µm thicknesses) were cut and subjected to H&E staining. For IHC 402 
staining, sections were deparaffinized and antigen retrieval was performed by incubation 403 
at 95 °C for 15 minutes in an antigen retrieval solution. Next, the sections were washed 404 
with PBS, blocked for 1 h at RT in 10% FBS, and stained as described above.  405 
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Re-analysis of published microarray data. The data obtained from published 406 
microarray data (GenBank accession number GSE4193 (34)) were normalized by using 407 
global median scaling, and were re-analyzed using GeneSpring (Agilent).  408 
Statistical analysis. Statistical analysis was performed using a two-tailed, non-paired 409 
Student’s t-Test. P-value <0.05 was considered statistically significant. 410 
 411 
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Figure legends 567 
Figure 1 568 
Expression of mouse homologues of human CTA genes whose expression is more than 569 
5% higher in cancer cell lines than in the corresponding normal tissues. Relative 570 
expression levels of CTA genes in liver (A), colon (B), bladder (C), ovary (D), lung (E) 571 
and breast (F) cancer cell lines and in the respective normal tissues are shown. The 572 
expression in Hepa1-6 (A, a), MH134-TC (A, b), colon-26 (B), MBT-2 (C), HM-1 (D, a), 573 
OV3121 (D, b), 3LL (E, a), KLN205 (E, b), Ehrlich (F, a), MM46 (F, b) and FM3A (F, c) 574 
was set as 1.0. Expression was determined by RT-qPCR using Dynamic Arrays on the 575 
BioMark System. 576 
 577 
Figure 2 578 
Expression of mouse homologues of human CTA genes whose expression is same or 579 
lower in cancer cell lines than in the corresponding normal tissues. Relative expression 580 
levels of CTA genes in liver (A), colon (B), bladder (C), ovary (D), lung (E), and breast 581 
(F) cancer cell lines and in the respective normal tissues are shown. The expression in 582 
normal tissues was set as 1.0. Expression was determined by RT-qPCR using Dynamic 583 




Figure 3 586 
siRNA screening of mouse CTA genes using the first cell lines. Changes in viability of 587 
liver (A), colon (B), bladder (C), ovary (D), lung (E), melanoma (F), and breast (G) 588 
cancer cell lines were tested using two different siRNAs (#1, #2) corresponding to the 589 
CTA genes whose expression was highest in the respective tested cell lines. Cell viability 590 
was determined by MTS assay at 72 hours after transfection with the siRNAs. Viability 591 
of KD cells relative to that of control cells is shown. Graphs represent data from two 592 
biological replicates. Dots indicate values from each of the two replicates. Horizontal 593 
solid red lines indicate 100% viability; broken red lines indicate 10% increased or 594 
decreased viability. Red text indicates genes for which KD (by at least one siRNA) 595 
caused a viability change of more than 10%.  596 
 597 
Figure 4 598 
siRNA screening of mouse CTA genes using the second cell lines. Changes of viability of 599 
liver (A), colon (B), bladder (C), ovary (D), lung (E), melanoma (F), and breast (G) 600 
cancer cell lines were tested using two different siRNAs (#1, #2) corresponding to the 601 
CTA genes selected by using the first cell lines. KD was carried out in the second cell 602 
lines, i.e., lines that showed the next highest level of expression of the tested genes. Cell 603 
viability was determined by MTS assay at 72 hours after transfection with the siRNAs. 604 
Viability of KD cells relative to that of control cells is shown. Graphs represent data from 605 
two biological replicates. Dots indicate values from each of the two replicates. Horizontal 606 
solid red lines show 100% viability; broken red lines indicate 10% increased or decreased 607 
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viability. Red text indicates genes for which KD (by at least one siRNA) caused a 608 
viability change of more than 10%.  609 
 610 
Figure 5 611 
Repression of G1-S transition of cell-cycle and cell survival, and increased nuclear 612 
localization of SMAD3, by Tekt5-KD in OV3121 and MH134-TC cells. (A, B) Changes 613 
of viability of an ovarian cancer cell line, OV3121 (A), and of a liver cancer cell line, 614 
MH134-TC (B), by two different siRNA corresponding to Tekt5 (siTekt5#1, siTekt5#2). 615 
siCTL: AllStars Negative Control siRNA. MH134-TC cells were assayed at 72 hours 616 
after transfection with the siRNAs. Cell viability was determined by MTS assay. (C, D) 617 
Decreased accumulation of Tekt5 mRNA as determined by RT-qPCR (C) and of TEKT5 618 
protein as determined by western blot (D, upper) after Tekt5-KD in OV3121 cells. For the 619 
western blotting, the signal intensity of TEKT5 was quantified and then normalized 620 
against that of the housekeeping protein glyceraldehyde-3- phosphate dehydrogenase 621 
(GAPDH) (D, lower). (E, F) Ratios of active-Caspase3-positive apoptotic cells (E) and of 622 
cells in each phase of the cell cycle (F) at 48 hours after transfection of OV3121 cells 623 
with Tekt5 siRNA (siTekt5#1), as determined by flow cytometry. (G) The accumulation 624 
of p27kip at 24 and 48 hours after transfection of OV3121 cells with Tekt5 siRNA, as 625 
determined by western blot (left). Signal intensity of p27kip was quantified and then 626 
normalized against that of GAPDH (right). (H) Localization of SMAD3 at 24 and 48 627 
hours after transfection of OV3121 cells with Tekt5 siRNA, as determined by 628 
immunostaining (left). SMAD3 accumulation is shown in red at 48 hours in the 629 
micrographs. Nuclear staining by DAPI (blue) also is shown. Scale bar: 50 μm. Signal 630 
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intensity of SMAD3 was quantified by confocal laser scan microscopy, and 631 
nuclear-cytoplasmic ratios of the protein were determined. N.D.: Not detected. Graphs 632 
represent data from three biological replicates. Values are plotted as mean ± SE. *p<0.05, 633 
**p<0.01, ***p<0.001 (two-tailed, non-paired Student’s t test).  634 
 635 
Figure 6 636 
Abnormality of microtubules in OV3121 cells subjected to Tekt5-KD. (A) Localization of 637 
β-III-tubulin (red) in Tekt5-KD (siTekt5) and control (siCTL) OV3121 cells, as detected 638 
by immunostaining. Fibrous β-III-tubulin is disrupted by Tekt5-KD. Inlets show 639 
DAPI-staining in higher magnification. Arrows indicate DAPI-stained dots. Scale bar 640 
=50 μm, 12.5 μm (inlets). (B) Localization of TEKT5 in OV3121 cells. TEKT5 (red) is 641 
not co-localized with β-III-tubulin (green). DAPI-staining (blue) also is shown. Scale bar 642 
=10 μm. (C-D) The accumulation of α-tubulin (C) and HDAC6 (D) protein in Tekt5-KD 643 
and control OV3121 cells, as detected by western blot at 24, 48, and 72 h 644 
post-transfection. For both (C) and (D), each panel consists of an image of the blot (left) 645 
and of results (ratios of acetylated (ac) α-tubulin to total α-tubulin (C, right) or of 646 
HDAC6 to GAPDH (D, right)) quantified by band intensity. (E) The accumulation of 647 
Hdac6 mRNA (D) in Tekt5-KD and control OV3121 cells, as detected by RT-qPCR at 48 648 
h post-transfection. For Panels (C-E), graphs represent data from three and five biological 649 
replicates for ac α-tubulin and HDAC6/Hdac6, respectively. Values are plotted as mean ± 650 
SE. *p<0.05, **p<0.01 (two-tailed, non-paired Student’s t test).  651 
 652 
Figure 7 653 
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The effect of tubastatin A (TBSA), a specific inhibitor of HDAC6, in OV3121 cells. (A) 654 
Disruption of β-III-tubulin (red) by Tekt5-KD in control (+DMSO) was rescued by TBSA. 655 
DAPI-staining (blue) also is shown. siCTL: AllStars Negative Control siRNA. Scale bar 656 
=50 μm. (B) Cell viability of Tekt5-KD OV3121 cells, but not that of control OV3121 657 
cells, at 72 h post-transfection was increased by TBSA exposure. Cell viability was 658 
determined by MTS assay. (C) A possible mechanism for TEKT5 control of cancer cell 659 
viability. PTM: Post-translational modification, Glu: glutamyl side chain, X: unknown 660 
factor (s) for polyglutamylation of tubulin. Values are plotted as mean ± SE. **p<0.01, 661 
***p<0.001 (two-tailed, non-paired Student’s t test).  662 
 663 
Figure 8 664 
The expression of Tekt5 in spermatogenic cells. (A) The graph represents signal intensity 665 
values normalized using global median scaling for Tekt5 gene expression; graph is based 666 
on published microarray data (GSE4193). Dots show average values from each of two 667 
independent data sets. TypeA SG: type A spermatogonia; TypeB SG: type B 668 
spermatogonia; PS: pachytene spermatocyte; RS: round spermatid. (B, C) The 669 
accumulation of TEKT5 (cyan), SYCP3 (red), and PNA (green) in 3-month-old mouse 670 
testis, as detected by immunostaining. Merged images with DAPI (blue) also are shown. 671 
Pictures in (C) show higher magnification images of spermatogenic cells in different 672 
differentiation stages classified based on the staining patterns of SYCP3 and PNA. Scale 673 
bars = 5 μm.  674 
 675 
Figure 9 676 
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Spermatogenic failure in Tekt5-KD testis at P22. (A) H&E staining of Tekt5-KD and 677 
control testes at 22 days of age (left). The graphs show ratios of abnormal seminiferous 678 
tubules in Tekt5-KD testis to those in control testis at P22 (left) and P29 (right). Error 679 
bars indicate ranges of minimum and maximum values; Xs and horizontal lines in boxes 680 
indicate means and medians, respectively. (B, C) Decreased accumulation of Tekt5 681 
mRNA (B) and TEKT5 protein (C) in Tekt5-KD testis compared to control testis. The 682 
expression of mRNA was determined by RT-qPCR (B). Signal intensity of TEKT5 683 
immunostaining (C, left) in early spermatocytes (early SC), late spermatocytes (late SC), 684 
and spermatids (ST) (with stages determined based on the staining patterns for SYCP3 685 
and PNA shown in Fig. 6C) was quantified; values were normalized to that in Leydig 686 
cells (C, right). Values in control germ cells were set as 1.0. (D) Decreased PNA-positive 687 
spermatids (green) in Tekt5-KD testis (left). SYCP3-expressing spermatocytes (red) are 688 
not affected by KD. Ratios of seminiferous tubules with PNA-positive cells (right). (E) 689 
Decreased acetylated (ac) α-tubulin (red) in Tekt5-KD testis at P22. Yellow and white 690 
arrow heads indicate PNA (green) -positive spermatids and PNA-negative spermatocytes, 691 
respectively (left). Signal intensity of ac α-tubulin immunostaining was quantified, and 692 
values were normalized to that in Leydig cells (right). Values in control germ cells were 693 
set as 1.0. (F) The graph represents signal intensity values normalized using global 694 
median scaling for Hdac6 gene expression based on published microarray data 695 
(GSE4193). Dots indicate average values from each of two independent data sets. TypeA 696 
SG: type A spermatogonia; TypeB SG: type B spermatogonia; PS: pachytene 697 
spermatocyte; RS: round spermatid. Blue shows DAPI staining. Scale bars = 200 μm (A), 698 
50 μm (C; D, lower), 75 μm (D, upper), 100 μm (E, upper), or 25 μm (E, lower). Graphs 699 
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represent data from six and nine mice at P22 and P29, respectively, following injection of 700 
Tekt5 siRNA and control siRNA in left and right testes, respectively. Values in B, C, and 701 
D are plotted as mean ± SE. *p<0.05, **p<0.01, ***p<0.001 (two-tailed, non-paired 702 
Student’s t test) 703 
 704 









